Drug Combinations Target Mutant BRAF Melanomas

This article originally appeared here.
Share this content:
Drug Combinations Target Mutant <i>BRAF</i> Melanomas
Drug Combinations Target Mutant BRAF Melanomas

(HealthDay News) -- Melanomas carrying mutations that make them resistant to many drugs can be effectively targeted by drug combinations, some of which include statins, according to a study published online Dec. 13 in Cancer Discovery.

Matthew A. Held, Ph.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues tested the efficacy of pairwise combinations of 40 small molecule compounds (of 150 tested as single agents) on melanoma cells containing activating mutations in the RAS gene, the BRAF gene (including melanomas resistant to vemurafenib, which targets BRAF mutations), or neither gene.

The researchers identified several effective inhibitor combinations. Melanomas with RAS mutations were generally more resistant to combination treatment than melanomas with BRAF mutations. However, in vitro and in vivo, they were sensitive to combinations of statins and cyclin-dependent kinase inhibitors. Simvastatin plus flavopiridol were also effective in reducing the growth of melanomas with mutated RAS in mice. Melanomas with BRAF mutations were sensitive to inhibitors of the EGF receptor and AKT, which also restored sensitivity to vemurafenib.

"We have used drug combinatorial screening to identify effective combinations for mutant BRAF melanomas, including those resistant to vemurafenib, and mutant RAS melanomas that are resistant to many therapies," Held and colleagues conclude.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs